|Dr. Jack W. Singer M.D.||Co-Founder, Chief Scientific Officer, Global Head-Translational Med, Interim CMO & Exec Director||522.99k||N/A||74|
|Mr. Bruce J. Seeley||Principal Financial Officer, Chief Commercial & Admin. Officer, Exec. VP and Sec.||503.35k||N/A||53|
|Dr. Matthew James Plunkett Ph.D.||Chief Bus. Officer and Exec. VP||499.31k||N/A||45|
|Dr. Adam R. Craig M.D., Ph.D., M.B.A.||Chief Exec. Officer, Pres and Director||N/A||N/A||51|
|Dr. Silvano Spinelli||Exec. VP of Devel. and Managing Director of European Operations||N/A||N/A||64|
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
CTI BioPharma Corp.’s ISS Governance QualityScore as of May 1, 2017 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 5; Compensation: 9.